Showing results (321-330 of 696) with videos related to

Sort By:
Pageof 70
Diabetes, Obesity & Metabolism|November 11, 2018
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markersHiddo J L Heerspink, C David Sjöström, Silvio E Inzucchi, et al.
Diabetes, Obesity & Metabolism|March 18, 2024
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trialStefan R Bornstein, Dick de Zeeuw, Hiddo J L Heerspink, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2020
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenoneRajiv Agarwal, Stefan D Anker, George Bakris, et al.
Platelets|October 27, 2009
Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivityInge Tarnow, Alan D Michelson, Marc R Barnard, et al.
International Journal of Circumpolar Health|March 21, 2023
The effect of diabetes and the diabetogenic TBC1D4 p.Arg684ter variant on kidney function in Inuit in GreenlandMaria Overvad, Lars Jorge Díaz, Peter Bjerregaard, et al.
Diagnostics (Basel, Switzerland)|August 27, 2021
Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATEEmilie H Zobel, Rasmus S Ripa, Bernt J von Scholten, et al.
Frontiers in Endocrinology|December 17, 2021
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME TrialJacob K Jensen, Emilie H Zobel, Bernt J von Scholten, et al.
Cardiovascular Diabetology|December 20, 2025
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOWPeter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, et al.
Diabetes|July 21, 2023
Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 DiabetesAsger Wretlind, Viktor R Curovic, Tommi Suvitaival, et al.
BMJ Open Diabetes Research & Care|October 14, 2021
Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetesTheis Bjerre-Christensen, Signe A Winther, Nete Tofte, et al.
Pageof 70